Cargando…
Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study
Background: Chronic tubulointerstitial fibrosis is a common final pathway leading to end stage kidney disease in cats and has no effective treatment. The use of cell-based molecules to treat kidney fibrosis may be a promising approach. The objectives were to test the effects of intra-renal chemokine...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969654/ https://www.ncbi.nlm.nih.gov/pubmed/33748219 http://dx.doi.org/10.3389/fvets.2021.646087 |
_version_ | 1783666270470668288 |
---|---|
author | Bennington, Julie Lankford, Shannon Magalhaes, Renata S. Shankle, Douglas Fanning, Jason Kartini, Cucu Suparto, Irma Kusumawardhani, Winda Putra, M. ArRaniri Mariya, Silmi Badlani, Gopal Williams, J. Koudy |
author_facet | Bennington, Julie Lankford, Shannon Magalhaes, Renata S. Shankle, Douglas Fanning, Jason Kartini, Cucu Suparto, Irma Kusumawardhani, Winda Putra, M. ArRaniri Mariya, Silmi Badlani, Gopal Williams, J. Koudy |
author_sort | Bennington, Julie |
collection | PubMed |
description | Background: Chronic tubulointerstitial fibrosis is a common final pathway leading to end stage kidney disease in cats and has no effective treatment. The use of cell-based molecules to treat kidney fibrosis may be a promising approach. The objectives were to test the effects of intra-renal chemokine CXCL12 injection in a pre-clinical cat model of unilateral ischemia/reperfusion (I/R)-induced kidney fibrosis and then, within a clinical pilot study, test the safety/feasibility of CXCL12 injection in cats that might have early chronic kidney disease (CKD). Methods: Pre-clinical: Thirty cats received intra-renal injection of 100, 200, or 400 ng of recombinant human CXCL12, or sterile saline, into the I/R kidney 70 days post-injury, or were non-injured, non-injected controls (n = 6/group). Kidney collagen content was quantified 4 months post-treatment using Masson's Trichrome and Picrosirius Red (PSR) stained tissues. In a separate study (n = 2) exploring short-term effects of CXCL12, 200 ng CXCL12 was injected into I/R kidneys and then harvested either 30 min (n = 1) or 1 month (n = 1) post-injection. Kidney concentrations of CXCL12, matrix metalloproteinase 1 (MMP-1), and lysyl oxidase-like enzyme 2 (LOXL-2) were quantified via ELISA. Clinical Pilot: 14 client-owned cats with potential early kidney disease received a single-treatment, bilateral intra-renal injection of 200 ng CXCL12 (n = 7), or received no injection (n = 7). Blood/urine samples were collected monthly for 9 months to assess renal function and CKD staging. Results: Pre-clinical: I/R increased the affected kidney collagen content, which both mid and high doses of CXCL12 restored to normal (ps < 0.05 vs. untreated). I/R increased collagen fiber width, which both mid and high doses of CXCL12 restored to normal (p < 0.001 vs. untreated). Early changes in kidney MMP-1, associated with collagen breakdown, and subsequent decreases in LOXL-2, associated with collagen cross-linking, in response to CXCL12 treatment may contribute to these findings. Clinical Pilot: Bilateral intra-renal injection of CXCL12 using ultrasound guidance in cats with CKD was feasible and safe in a general practice clinical setting with no obvious side effects noted during the 9-month follow-up period. Conclusions: Intra-renal injection of CXCL12 may prove to be an effective treatment for kidney fibrosis in cats with CKD. Additional mechanistic and clinical evaluations are needed. |
format | Online Article Text |
id | pubmed-7969654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79696542021-03-19 Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study Bennington, Julie Lankford, Shannon Magalhaes, Renata S. Shankle, Douglas Fanning, Jason Kartini, Cucu Suparto, Irma Kusumawardhani, Winda Putra, M. ArRaniri Mariya, Silmi Badlani, Gopal Williams, J. Koudy Front Vet Sci Veterinary Science Background: Chronic tubulointerstitial fibrosis is a common final pathway leading to end stage kidney disease in cats and has no effective treatment. The use of cell-based molecules to treat kidney fibrosis may be a promising approach. The objectives were to test the effects of intra-renal chemokine CXCL12 injection in a pre-clinical cat model of unilateral ischemia/reperfusion (I/R)-induced kidney fibrosis and then, within a clinical pilot study, test the safety/feasibility of CXCL12 injection in cats that might have early chronic kidney disease (CKD). Methods: Pre-clinical: Thirty cats received intra-renal injection of 100, 200, or 400 ng of recombinant human CXCL12, or sterile saline, into the I/R kidney 70 days post-injury, or were non-injured, non-injected controls (n = 6/group). Kidney collagen content was quantified 4 months post-treatment using Masson's Trichrome and Picrosirius Red (PSR) stained tissues. In a separate study (n = 2) exploring short-term effects of CXCL12, 200 ng CXCL12 was injected into I/R kidneys and then harvested either 30 min (n = 1) or 1 month (n = 1) post-injection. Kidney concentrations of CXCL12, matrix metalloproteinase 1 (MMP-1), and lysyl oxidase-like enzyme 2 (LOXL-2) were quantified via ELISA. Clinical Pilot: 14 client-owned cats with potential early kidney disease received a single-treatment, bilateral intra-renal injection of 200 ng CXCL12 (n = 7), or received no injection (n = 7). Blood/urine samples were collected monthly for 9 months to assess renal function and CKD staging. Results: Pre-clinical: I/R increased the affected kidney collagen content, which both mid and high doses of CXCL12 restored to normal (ps < 0.05 vs. untreated). I/R increased collagen fiber width, which both mid and high doses of CXCL12 restored to normal (p < 0.001 vs. untreated). Early changes in kidney MMP-1, associated with collagen breakdown, and subsequent decreases in LOXL-2, associated with collagen cross-linking, in response to CXCL12 treatment may contribute to these findings. Clinical Pilot: Bilateral intra-renal injection of CXCL12 using ultrasound guidance in cats with CKD was feasible and safe in a general practice clinical setting with no obvious side effects noted during the 9-month follow-up period. Conclusions: Intra-renal injection of CXCL12 may prove to be an effective treatment for kidney fibrosis in cats with CKD. Additional mechanistic and clinical evaluations are needed. Frontiers Media S.A. 2021-03-04 /pmc/articles/PMC7969654/ /pubmed/33748219 http://dx.doi.org/10.3389/fvets.2021.646087 Text en Copyright © 2021 Bennington, Lankford, Magalhaes, Shankle, Fanning, Kartini, Suparto, Kusumawardhani, Putra, Mariya, Badlani and Williams. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Veterinary Science Bennington, Julie Lankford, Shannon Magalhaes, Renata S. Shankle, Douglas Fanning, Jason Kartini, Cucu Suparto, Irma Kusumawardhani, Winda Putra, M. ArRaniri Mariya, Silmi Badlani, Gopal Williams, J. Koudy Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study |
title | Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study |
title_full | Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study |
title_fullStr | Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study |
title_full_unstemmed | Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study |
title_short | Chemokine Therapy in Cats With Experimental Renal Fibrosis and in a Kidney Disease Pilot Study |
title_sort | chemokine therapy in cats with experimental renal fibrosis and in a kidney disease pilot study |
topic | Veterinary Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7969654/ https://www.ncbi.nlm.nih.gov/pubmed/33748219 http://dx.doi.org/10.3389/fvets.2021.646087 |
work_keys_str_mv | AT benningtonjulie chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT lankfordshannon chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT magalhaesrenatas chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT shankledouglas chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT fanningjason chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT kartinicucu chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT supartoirma chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT kusumawardhaniwinda chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT putramarraniri chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT mariyasilmi chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT badlanigopal chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy AT williamsjkoudy chemokinetherapyincatswithexperimentalrenalfibrosisandinakidneydiseasepilotstudy |